Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
SCYX
#3582
SCYNEXIS, Inc.
0.7
5
+4.17%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+4.17%
Aylık değişim
-6.25%
6 aylık değişim
-9.64%
Yıllık değişim
-25.00%
Önceki kapanış
0.7
2
Open
0.7
5
Bid
Ask
Low
0.7
5
High
0.7
5
Hacim
3
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
SCYX
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
37.95 M
38.98 M
39.02 M
41.92 M
41.97 M
—
Valuation ratios
Enterprise value
27.81 M
31.12 M
30.21 M
17.27 M
17.52 M
96.11 M
Price to earnings ratio
-2.22
-2.75
-1.7
-1.69
-1.51
-7.65
Price to sales ratio
8.43
15.67
17.6
10.17
12.95
56.4
Price to cash flow ratio
11.39
2.44
1.69
1.38
1.13
6.64
Price to book ratio
0.27
1.07
0.21
0.16
0.2
1.63
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.03
0.04
0.08
0.11
0.17
0.4
Return on equity %
0.05
0.07
0.11
0.15
0.24
0.56
Return on invested capital %
117.8
124.08
132.56
316.45
504.05
1 077.13
Gross margin %
100
100
100
100
100
400
Operating margin %
1 563.64
824.16
3 350.19
700.95
2 516.47
7 391.77
EBITDA margin %
—
—
—
—
—
—
Net margin %
425.45
369.6
2 097.67
504.77
2 572.16
5 544.19
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
3.13
3
5.83
5.2
5.75
19.78
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.01
0.01
0
0.02
0.01
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
0
0
0
—
Long term debt to total equity ratio
—
—
0
0
0
—
Per share metrics
Operating cash flow per share
-0.02
0.2
0.15
0.15
0.17
0.68
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
1.75
1.55
1.09
0.93
0.76
4.33
Net current asset value per share
1.65
1.49
1.06
1.14
0.98
4.66
Tangible book value per share
1.2
1.14
1.02
0.89
0.73
3.78
Working capital per share
1.13
0.99
0.88
0.92
0.81
3.59
Book value per share
1.2
1.14
1.02
0.89
0.73
3.78
Haberler
SCYNEXIS doses first patients in SCY-247 IV formulation trial
FDA, SCYNEXIS ilacına hızlı izin ve QIDP statüsü verdi
JERSEY CITY - FDA grants fast track and QIDP designations to SCYNEXIS drug
Scynexis receives 180-day extension from Nasdaq to meet listing requirements
SCYNEXIS, mantar enfeksiyonu araştırması için yıllık 7 milyon dolarlık hibe alıyor
SCYNEXIS receives $7 million annual grant for antifungal research
Guggenheim, GSK ile yapılan anlaşma sonrası SCYNEXIS hisse fiyat hedefini 3 dolara düşürdü
Guggenheim lowers SCYNEXIS stock price target to $3 after GSK trial resolution
SCYNEXIS receives $22 million from GSK as MARIO study ends
Scynexis, GSK ile yeni anlaşma kapsamında MARIO çalışması sona ererken 24,3 milyon dolar alacak
Scynexis to receive $24.3 million from GSK as MARIO study ends per new agreement
SCYNEXIS reports positive Phase 1 results for antifungal drug SCY-247